Evidence map›Paper›PMID 40017103›Full record

ArticleCancer science2025

High Antigenicity for T

Hiroaki Matsuura, Takamasa Ishino, Toshifumi Ninomiya, Kiichiro Ninomiya, Kota Tachibana, Akiko Honobe-Tabuchi, Yoshinori Muto, Takashi Inozume, Youki Ueda, Kadoaki Ohashi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroaki MatsuuraDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.ORCID https://orcid.org/0009-0009-5041-3042
Takamasa IshinoDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.
Toshifumi NinomiyaDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.
Kiichiro NinomiyaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan.
Kota TachibanaDepartment of Dermatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Akiko Honobe-TabuchiDepartment of Dermatology, University of Yamanashi, Yamanashi, Japan.
Yoshinori MutoDepartment of Dermatology, University of Yamanashi, Yamanashi, Japan.
Takashi InozumeDepartment of Dermatology, University of Yamanashi, Yamanashi, Japan.
Youki UedaDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.
Kadoaki OhashiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan.ORCID https://orcid.org/0000-0002-5180-3933
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan.
Joji NagasakiDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.
Yosuke TogashiDepartment of Tumor Microenvironment, Okayama University, Okayama, Japan.ORCID https://orcid.org/0000-0001-9910-0164

Funding

Canon Foundation for Scientific ResearchDaiichi Sankyo Foundation of Life ScienceJapan Agency for Medical Research and Development JP23ama221324h0001Japanese Respiratory FoundationJapan Science and Technology Agency JPMJFR2049Japan Society for the Promotion of Science JP20H03694Japan Society for the Promotion of Science JP21K20859Japan Society for the Promotion of Science JP22K15607MSD Life Science Foundation, Public Interest Incorporated FoundationRyobi Teien Memory FoundationUBE Foundation
6 · The paper itself

Abstract

Regulatory T (T

Indexed as

Drug Resistance, NeoplasmImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryAnimalsAntibodies, MonoclonalCell Line, TumorCTLA-4 AntigenFemaleHumansMiceMice, Inbred C57BLAntibodies, MonoclonalCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorantigenicitycancer immunotherapyCTLA‐4PD‐1regulatory T cell

Identifiers

PMID40017103
PMCPMC12044662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.